Overview

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of injections of rAvPAL-PEG in subjects with PKU.
Phase:
Phase 1
Details
Lead Sponsor:
BioMarin Pharmaceutical